Cargando…

Positive associations between galectin-3 and PSA levels in prostate cancer patients: a prospective clinical study-I

Galectin-3 (Gal-3), an oncogenic pro-inflammatory protein, has been suggested as a possible complementary diagnostic candidate to prostate specific antigen (PSA) blood test for prostate cancer patients. The presence of the proteins in the circulation (biomarkers) may elicit an intrinsic humoral immu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nakajima, Kosei, Heilbrun, Lance K, Hogan, Victor, Smith, Daryn, Heath, Elisabeth, Raz, Avraham
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5347690/ https://www.ncbi.nlm.nih.gov/pubmed/27741512 http://dx.doi.org/10.18632/oncotarget.12619

Ejemplares similares

The influence of PSA autoantibodies in prostate cancer patients: a prospective clinical study-II
por: Nakajima, Kosei, et al.
Publicado: (2016)

Galectin-3: a possible complementary marker to the PSA blood test
por: Balan, Vitaly, et al.
Publicado: (2013)

Galectin-3 Inhibits Osteoblast Differentiation through Notch Signaling()()
por: Nakajima, Kosei, et al.
Publicado: (2014)

Extracellular galectin-3 programs multidrug resistance through Na+/K+-ATPase and P-glycoprotein signaling
por: Harazono, Yosuke, et al.
Publicado: (2015)

Galectin-3: an immune checkpoint target for musculoskeletal tumor patients
por: Nakajima, Kosei, et al.
Publicado: (2020)

Galectin-3 leads to attenuation of apoptosis through Bax heterodimerization in human thyroid carcinoma cells
por: Harazono, Yosuke, et al.
Publicado: (2014)

Pilot Phase II Trial of Bevacizumab Monotherapy in Nonmetastatic Castrate-Resistant Prostate Cancer
por: Ogita, Shin, et al.
Publicado: (2012)

Galectin-3 regulates p21 stability in human prostate cancer cells
por: Wang, Yi, et al.
Publicado: (2012)

Chimeric galectin-3 and collagens: Biomarkers and potential therapeutic targets in fibroproliferative diseases
por: Nangia-Makker, Pratima, et al.
Publicado: (2022)

A Phase 1 study Combining Pexidartinib, Radiation Therapy, and Androgen Deprivation Therapy in Men With Intermediate- and High-Risk Prostate Cancer
por: Hamid, Muhammad, et al.
Publicado: (2021)

MRI- and PET-Based Assessment of Radiological and Clinical Factors Associated With Cervical Cancer Response to External Beam Radiation Therapy
por: Paul, Arun G, et al.
Publicado: (2022)

Galectins as Cancer Biomarkers
por: Balan, Vitaly, et al.
Publicado: (2010)

Autocrine motility factor and its receptor expression in musculoskeletal tumors
por: Nakajima, Kosei, et al.
Publicado: (2020)

Amplification of autocrine motility factor and its receptor in multiple myeloma and other musculoskeletal tumors
por: Nakajima, Kosei, et al.
Publicado: (2020)

Calpain activation through galectin-3 inhibition sensitizes prostate cancer cells to cisplatin treatment
por: Wang, Y, et al.
Publicado: (2010)

Regulation of Tumor Progression by Extracellular Galectin-3
por: Nangia-Makker, Pratima, et al.
Publicado: (2008)

Clinical Efficacy of Enzalutamide vs Bicalutamide Combined With Androgen Deprivation Therapy in Men With Metastatic Hormone-Sensitive Prostate Cancer: A Randomized Clinical Trial
por: Vaishampayan, Ulka N., et al.
Publicado: (2021)

Urinary PSA and Serum PSA for Aggressive Prostate Cancer Detection
por: Höti, Naseruddin, et al.
Publicado: (2023)

Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy‐Naive Metastatic Castrate‐Resistant Prostate Cancer
por: Heath, Elisabeth, et al.
Publicado: (2019)

Nadir PSA level and time to nadir PSA are prognostic factors in patients with metastatic prostate cancer
por: Tomioka, Atsushi, et al.
Publicado: (2014)

Association of Polymorphisms in the Prostate-Specific Antigen (PSA) Gene Promoter with Serum PSA Level and PSA Changes after Dutasteride Treatment in Korean Men with Benign Prostatic Hypertrophy
por: Park, Sung Woon, et al.
Publicado: (2010)

Association of serum prostate-specific antigen (PSA) level and circulating tumor cell-based PSA mRNA in prostate cancer
por: Cho, Hyungseok, et al.
Publicado: (2022)

Genetically adjusted PSA levels for prostate cancer screening
por: Kachuri, Linda, et al.
Publicado: (2023)

Contribution of allelic variability in prostate specific antigen (PSA) & androgen receptor (AR) genes to serum PSA levels in men with prostate cancer
por: Chavan, Sushant V., et al.
Publicado: (2014)

Does normalizing PSA after successful treatment of chronic prostatitis with high PSA value exclude prostatic biopsy?
por: Azab, Sherif, et al.
Publicado: (2012)

Prospective validation of %p2PSA and the Prostate Health Index, in prostate cancer detection in initial prostate biopsies of Asian men, with total PSA 4–10 ng ml(−1)
por: Tan, Lincoln GL, et al.
Publicado: (2017)

The Complex Biological Effects of Pectin: Galectin-3 Targeting as Potential Human Health Improvement?
por: Pedrosa, Lucas de Freitas, et al.
Publicado: (2022)

Detection of prostate cancer with complexed PSA and complexed/total PSA ratio - is there any advantage?
por: Strittmatter, F, et al.
Publicado: (2011)

Is PSA density of the peripheral zone as a useful predictor for prostate cancer in patients with gray zone PSA levels?
por: Lee, Jaegeun, et al.
Publicado: (2021)

The Relationship between Prostate Biopsy Results and PSA and Free PSA Ratio Changes in Elevated Serum PSA Patients with and without Antibiotherapy
por: Duran, Mesut Berkan, et al.
Publicado: (2020)

A Comparative Performance Analysis of Total PSA, Percentage Free PSA, PSA Velocity, and PSA Density versus the Detection of Primary Circulating Prostate Cells in Predicting Initial Prostate Biopsy Findings in Chilean Men
por: Murray, Nigel P., et al.
Publicado: (2014)

Glycodendrimers and Modified ELISAs: Tools to Elucidate Multivalent Interactions of Galectins 1 and 3
por: Wolfenden, Mark, et al.
Publicado: (2015)

Phase II Study of Gemcitabine and Docetaxel Combination in Patients with Previously Treated Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
por: Kafri, Zyad, et al.
Publicado: (2012)

Pretreatment PSA levels affects the completion rate of Ra-223 treatment
por: Utsumi, Nobuko, et al.
Publicado: (2021)

Multivalent scaffolds induce galectin-3 aggregation into nanoparticles
por: Goodman, Candace K, et al.
Publicado: (2014)

Zonal adjusted PSA density improves prostate cancer detection rates compared with PSA in Taiwanese males with PSA < 20 ng/ml
por: Chang, Tsung-Hsin, et al.
Publicado: (2020)

Antigenic determinants of prostate-specific antigen (PSA) and development of assays specific for different forms of PSA.
por: Nilsson, O., et al.
Publicado: (1997)

Time to PSA rise differentiates the PSA bounce after HDR and LDR brachytherapy of prostate cancer
por: Burchardt, Wojciech, et al.
Publicado: (2018)

Long-Term Survival and PSA Control with Radiation and Immunotherapy for Node Positive Prostate Cancer
por: Kamrava, M., et al.
Publicado: (2009)

Assessment of PSA-Age volume score in predicting positive prostate biopsy findings in Turkey
por: Uçer, Oktay, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_0iec972044e2b6qlpqviu7i4bi